FTC Generic Drug Survey To Gather Information On Late-Listed Patents
This article was originally published in The Tan Sheet
Executive Summary
A Federal Trade Commission inquiry into generic drug competition will include an examination of late-listed patents.
You may also be interested in...
Generic Delay Tactics Evolving In Wake Of Consent Decrees – Initial FTC Data
Potentially anticompetitive strategies on generics have evolved since the Federal Trade Commission began imposing consent agreements on companies that made questionable settlements, FTC states
Generic Delay Tactics Evolving In Wake Of Consent Decrees – Initial FTC Data
Potentially anticompetitive strategies on generics have evolved since the Federal Trade Commission began imposing consent agreements on companies that made questionable settlements, FTC states
Generic Delay Tactics Evolving In Wake Of Consent Decrees – Initial FTC Data
Potentially anticompetitive strategies on generics have evolved since the Federal Trade Commission began imposing consent agreements on companies that made questionable settlements, FTC states